Compound ID | 1240
Class: Lipopolysaccharide synthesis inhibitor (LpxC inhibitor)
Spectrum of activity: | Gram-negative |
Details of activity: | Urinary tract infections caused by E. coli, K. pneumoniae, P. mirabilisincluding multi-drug resistant strains |
Institute where first reported: | Entasis Therapeutics |
Highest developmental phase: | Preclinical |
Development status: | Active |